Literature DB >> 26806120

Catheter ablation of atrial fibrillation in patients with concomitant sinus bradycardia-Insights from the German Ablation Registry.

Maura M Zylla1, Johannes Brachmann2, Thorsten Lewalter3, Ellen Hoffmann4, Karl-Heinz Kuck5, Dietrich Andresen6, Stephan Willems7, Matthias Hochadel8, Jochen Senges8, Hugo A Katus1, Dierk Thomas9.   

Abstract

AIMS: This investigation addresses procedural characteristics of catheter ablation in patients with atrial fibrillation (AF) and sinus bradycardia.
METHODS: From the prospective, multi-center German Ablation Registry 1073 patients with sinus rhythm at the time of AF ablation were divided into two groups according to heart rate at start of procedure (A, <60 beats per minute (bpm), n=197; B, 60-99bpm, n=876).
RESULTS: Acute procedural success was high (≥98%) and similar between groups. Procedure duration and energy application time were increased in group A (180min vs. 155min and 2561s vs. 1879s, respectively). Major complications were more frequent in group A (2.2% vs. 0.5%), and a greater proportion of these patients was discharged under antiarrhythmic medication (64% vs. 52%).
CONCLUSION: Catheter ablation of AF with concomitant sinus bradycardia is associated with high procedural efficacy, longer procedure- and energy application durations, and a slightly elevated complication rate.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Complications; Registry; Sinus bradycardia; Sinus node disease

Mesh:

Year:  2015        PMID: 26806120     DOI: 10.1016/j.jelectrocard.2015.12.007

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  1 in total

1.  Cryoballoon pulmonary vein isolation-mediated rise of sinus rate in patients with paroxysmal atrial fibrillation.

Authors:  Lara Wagner; Fabrice F Darche; Dierk Thomas; Patrick Lugenbiel; Panagiotis Xynogalos; Svenja Seide; Eberhard P Scholz; Hugo A Katus; Patrick A Schweizer
Journal:  Clin Res Cardiol       Date:  2020-05-13       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.